Leukemia Clinical Trials in Tennessee

Showing 921-940 of 1,766 trials

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more

Blueprint Medicines Corporation20 participantsStarted Jan 2022

Boston, Massachusetts, United States • Detroit, Michigan, United States • New York, New York, United States +4 more locations

UNKNOWNPhase 1/229 miles

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

NCT05268666

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.

Locally Advanced Solid TumorMetastatic Solid Tumor

Jubilant Therapeutics Inc.126 participantsStarted Apr 2022

Denver, Colorado, United States • Cincinnati, Ohio, United States • Nashville, Tennessee, United States +1 more locations

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Leukemia Trials in Other Cities

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial

Safety Study of SEA-CD40 in Cancer Patients

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Kenota 1 CWS Method Comparison Validation Study

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Study of ASN003 in Subjects With Advanced Solid Tumors

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Other Conditions in Tennessee